Daewoong Pharma
KRX:069620
Daewoong Pharma
KRX:069620
Price:
138 700
KRW
-0.93%
Market Closed
Market Cap:
1.6T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Daewoong Pharma
138700
-1300 (-0.93%)
| 52 Week Range |
99 900
150 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Daewoong Pharma
Balance Sheet
Balance Sheet Decomposition
Daewoong Pharma
Daewoong Pharma
| Current Assets | 574.8B |
| Cash & Short-Term Investments | 137.7B |
| Receivables | 178B |
| Other Current Assets | 259.2B |
| Non-Current Assets | 1.2T |
| Long-Term Investments | 273.9B |
| PP&E | 521.9B |
| Intangibles | 297.5B |
| Other Non-Current Assets | 102.2B |
| Current Liabilities | 667.1B |
| Accounts Payable | 101.1B |
| Accrued Liabilities | 26.6B |
| Short-Term Debt | 167.4B |
| Other Current Liabilities | 372B |
| Non-Current Liabilities | 335.9B |
| Long-Term Debt | 66.9B |
| Other Non-Current Liabilities | 268.9B |
Balance Sheet
Daewoong Pharma
Daewoong Pharma
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
63 648
|
59 936
|
78 280
|
91 121
|
65 334
|
32 094
|
72 300
|
75 907
|
102 951
|
111 506
|
|
| Cash |
13
|
163
|
142
|
183
|
148
|
324
|
185
|
152
|
243
|
17
|
|
| Cash Equivalents |
63 635
|
59 773
|
78 138
|
90 938
|
65 186
|
31 770
|
72 115
|
75 755
|
102 708
|
111 489
|
|
| Short-Term Investments |
118 383
|
91 853
|
82 554
|
55 863
|
67 043
|
97 737
|
104 821
|
97 827
|
37 700
|
26 179
|
|
| Total Receivables |
102 957
|
142 354
|
173 501
|
169 987
|
178 938
|
205 787
|
147 652
|
159 635
|
179 243
|
177 954
|
|
| Accounts Receivables |
95 500
|
134 313
|
159 645
|
156 546
|
161 678
|
167 970
|
119 298
|
122 904
|
142 341
|
137 715
|
|
| Other Receivables |
7 457
|
8 041
|
13 856
|
13 441
|
17 260
|
37 817
|
28 354
|
36 731
|
36 901
|
40 239
|
|
| Inventory |
111 864
|
144 508
|
162 746
|
187 016
|
190 924
|
179 892
|
175 735
|
170 559
|
208 736
|
241 545
|
|
| Other Current Assets |
6 934
|
14 453
|
10 377
|
14 145
|
13 426
|
10 747
|
27 844
|
16 473
|
20 339
|
37 462
|
|
| Total Current Assets |
403 787
|
453 105
|
507 459
|
518 132
|
515 666
|
526 256
|
528 351
|
520 401
|
548 968
|
574 824
|
|
| PP&E Net |
160 110
|
255 844
|
367 080
|
396 158
|
401 129
|
391 708
|
393 690
|
395 866
|
440 890
|
521 919
|
|
| PP&E Gross |
160 110
|
255 844
|
367 080
|
396 158
|
401 129
|
391 708
|
393 690
|
395 866
|
440 890
|
521 919
|
|
| Accumulated Depreciation |
119 730
|
160 930
|
176 451
|
203 087
|
224 776
|
248 025
|
273 185
|
294 821
|
317 813
|
333 424
|
|
| Intangible Assets |
31 326
|
75 874
|
90 153
|
113 127
|
88 725
|
103 838
|
117 894
|
164 321
|
205 160
|
236 637
|
|
| Goodwill |
84
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
|
| Note Receivable |
0
|
118
|
2 907
|
2 808
|
2 172
|
1 000
|
1 523
|
570
|
5 902
|
2 747
|
|
| Long-Term Investments |
94 956
|
93 737
|
105 547
|
103 312
|
111 846
|
124 615
|
225 573
|
196 927
|
219 903
|
273 864
|
|
| Other Long-Term Assets |
4 002
|
5 003
|
10 707
|
19 140
|
27 460
|
37 403
|
39 029
|
71 754
|
81 670
|
99 472
|
|
| Other Assets |
84
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
60 848
|
|
| Total Assets |
694 264
N/A
|
944 529
+36%
|
1 144 700
+21%
|
1 213 525
+6%
|
1 207 846
0%
|
1 245 668
+3%
|
1 366 908
+10%
|
1 410 687
+3%
|
1 563 341
+11%
|
1 770 311
+13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
36 487
|
45 467
|
61 381
|
59 441
|
62 259
|
76 703
|
78 785
|
70 852
|
83 401
|
101 099
|
|
| Accrued Liabilities |
4 728
|
9 509
|
5 071
|
7 719
|
11 103
|
5 946
|
10 654
|
20 608
|
24 975
|
26 625
|
|
| Short-Term Debt |
4 851
|
7 481
|
7 871
|
5 790
|
7 499
|
9 415
|
57 053
|
56 109
|
141 742
|
167 426
|
|
| Current Portion of Long-Term Debt |
0
|
39 963
|
99 882
|
89 936
|
199 865
|
90 915
|
90 910
|
200 865
|
93 114
|
206 903
|
|
| Other Current Liabilities |
33 613
|
47 017
|
48 627
|
105 162
|
86 675
|
79 101
|
89 348
|
112 226
|
129 600
|
165 064
|
|
| Total Current Liabilities |
79 680
|
149 437
|
222 832
|
268 049
|
367 401
|
262 080
|
326 750
|
460 660
|
472 831
|
667 117
|
|
| Long-Term Debt |
139 512
|
189 410
|
289 165
|
289 336
|
179 486
|
292 601
|
297 728
|
188 721
|
211 855
|
66 941
|
|
| Deferred Income Tax |
0
|
10 019
|
9 121
|
8 191
|
5 126
|
2 944
|
4 146
|
3 580
|
4 053
|
5 009
|
|
| Minority Interest |
12 426
|
100 169
|
105 058
|
112 098
|
113 677
|
116 606
|
144 255
|
128 384
|
133 206
|
144 978
|
|
| Other Liabilities |
19 566
|
15 422
|
19 031
|
16 412
|
48 024
|
52 124
|
43 035
|
59 811
|
133 378
|
118 963
|
|
| Total Liabilities |
251 184
N/A
|
464 457
+85%
|
645 207
+39%
|
694 086
+8%
|
713 714
+3%
|
726 354
+2%
|
815 914
+12%
|
841 156
+3%
|
955 323
+14%
|
1 003 008
+5%
|
|
| Equity | |||||||||||
| Common Stock |
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
28 966
|
|
| Retained Earnings |
357 774
|
396 820
|
416 622
|
442 014
|
422 884
|
445 415
|
452 802
|
467 361
|
504 294
|
618 864
|
|
| Additional Paid In Capital |
97 964
|
97 962
|
99 464
|
96 560
|
96 632
|
97 213
|
91 211
|
90 855
|
88 788
|
89 943
|
|
| Unrealized Security Profit/Loss |
3 740
|
1 371
|
588
|
111
|
6 131
|
4 516
|
197
|
33 114
|
26 554
|
23 733
|
|
| Treasury Stock |
44 916
|
44 916
|
44 916
|
44 916
|
44 916
|
44 916
|
29 236
|
18 360
|
18 360
|
2 850
|
|
| Other Equity |
449
|
133
|
1 231
|
3 075
|
3 303
|
2 849
|
7 055
|
33 822
|
30 882
|
56 112
|
|
| Total Equity |
443 080
N/A
|
480 072
+8%
|
499 493
+4%
|
519 439
+4%
|
494 133
-5%
|
519 315
+5%
|
550 994
+6%
|
569 531
+3%
|
608 017
+7%
|
767 303
+26%
|
|
| Total Liabilities & Equity |
694 264
N/A
|
944 529
+36%
|
1 144 700
+21%
|
1 213 525
+6%
|
1 207 846
0%
|
1 245 668
+3%
|
1 366 908
+10%
|
1 410 687
+3%
|
1 563 341
+11%
|
1 770 311
+13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
10
|
10
|
10
|
10
|
10
|
10
|
11
|
11
|
11
|
12
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
